Pomalidomide, Anti-PD-1 Antibody Combined With Selinexor (PPS) in Relapsed/Refractory Primary Central Nervous System Diffuse Large B-Cell Lymphoma

Primary central nervous system diffuse large B-cell lymphoma (PCNSL-DLBCL) is a highly aggressive malignancy accounting for over 80% of primary CNS lymphomas, with an annual incidence of 0.4-0.6 per 100,000 people globally and a rising trend in immunocompetent patients. First-line high-dose methotrexate-based chemotherapy causes severe toxicities and nearly 50% of patients relapse within 1-2 years, developing relapsed/refractory (R/R) disease. Treatment options for R/R PCNSL are scarce, with low response rates, median survival of only 3-6 months, and 5-year survival below 5%. The blood-brain

Trial Details

NCT ID

NCT07523737

Phase

PHASE2

Sponsor

Beijing Tongren Hospital

Status

RECRUITING

Cancer Type

Lymphoma

Interventions

Pomalidomide
PD-1 / PD-L1 monoclonal antibody
XPO1 inhibitor

Locations (sample)

Beijing, Beijing Municipality, China|39.9075,116.39723

Key Eligibility Criteria

Histologically confirmed primary central nervous system diffuse large B-cell lymphoma (PCNSL-DLBCL).
Disease progression or relapse after prior treatment with high-dose methotrexate and/or BTK inhibitors.
Age between 18 and 75 years.
ECOG performance status score 0-4.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →